US 10,376,522 B2
Triarylmethane analogs and their use in treating cancers
Jack L. Arbiser, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US); and U.S. Government as Represented by the Dept. of VA, Washington, DC (US)
Filed by Emory University, Atlatna, GA (US); and U.S. Government as Represented by The Department of Veterans Affairs, Washington, DC (US)
Filed on Jun. 6, 2016, as Appl. No. 15/173,946.
Application 15/173,946 is a continuation of application No. 13/412,895, filed on Mar. 6, 2012, granted, now 9,358,226.
Application 13/412,895 is a continuation of application No. 12/345,652, filed on Dec. 29, 2008, abandoned.
Claims priority of provisional application 61/090,027, filed on Aug. 19, 2008.
Claims priority of provisional application 61/009,745, filed on Dec. 31, 2007.
Prior Publication US 2017/0000801 A1, Jan. 5, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/55 (2006.01); A61K 9/127 (2006.01); C07D 223/28 (2006.01); A61K 31/136 (2006.01); A61K 31/14 (2006.01); A61K 31/353 (2006.01); A61K 31/404 (2006.01); A61K 31/422 (2006.01); A61K 31/428 (2006.01); A61K 31/47 (2006.01); A61K 31/4706 (2006.01); A61K 31/4709 (2006.01); A61K 31/54 (2006.01); A61K 31/553 (2006.01); A61K 31/662 (2006.01); C07D 223/26 (2006.01); C07F 9/40 (2006.01); C07D 215/26 (2006.01); C07D 215/46 (2006.01); C07D 263/32 (2006.01); C07D 275/06 (2006.01); C07D 279/28 (2006.01); C07D 311/36 (2006.01)
CPC A61K 31/55 (2013.01) [A61K 9/127 (2013.01); A61K 31/136 (2013.01); A61K 31/14 (2013.01); A61K 31/353 (2013.01); A61K 31/404 (2013.01); A61K 31/422 (2013.01); A61K 31/428 (2013.01); A61K 31/47 (2013.01); A61K 31/4706 (2013.01); A61K 31/4709 (2013.01); A61K 31/54 (2013.01); A61K 31/553 (2013.01); A61K 31/662 (2013.01); C07D 215/26 (2013.01); C07D 215/46 (2013.01); C07D 223/26 (2013.01); C07D 223/28 (2013.01); C07D 263/32 (2013.01); C07D 275/06 (2013.01); C07D 279/28 (2013.01); C07D 311/36 (2013.01); C07F 9/4056 (2013.01); C07F 9/4059 (2013.01)] 4 Claims
 
1. A pharmaceutical composition comprising liposomes containing a compound defined by the formula below

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, wherein
n is 1-4;
R is H or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, or arylalkyl;
X is H, amino, hydroxy, ether, thiol, or thiolether; and
Z is an optional substituent selected from halo, hydroxyl, thiol, ester, amide, carboxy, sulfoxy, nitrile, azido, alkyl, alkenyl, alkynyl, nitro, amino, aryl, heteroaryl, phosphonate, and fulvene.